<DOC>
	<DOCNO>NCT01408576</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability long-term epratuzumab treatment subject Systemic Lupus Erythematosus ( SLE )</brief_summary>
	<brief_title>Open Label Extension Study Epratuzumab Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Treatment period extend 2 year total 4 year amendment prepare accordingly .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Subject complete doubleblind study SL0009 ( NCT01262365 ) SL0010 ( NCT01261793 ) terminate prematurely Week 16 later SL0009 SL0010 due lack efficacy would , opinion investigator , continue benefit continued epratuzumab treatment Subject complete openlabel study SL0006 ( NCT00383513 ) SL0008 ( NCT00660881 ) , would , opinion investigator , continue benefit continued epratuzumab treatment Women childbearing potential must agree use acceptable method birth control Subjects active , severe , neuropsychiatric SLE , define neuropsychiatric element score British Isles Lupus Assessment Group Index ( BILAG ) level A disease Subjects active , severe SLE disease activity involve renal system Subjects concurrent relevant medical condition like define chronic infection high risk new significant infection Substance abuse dependence History malignant cancer Subjects condition , investigator 's judgment , would make subject unsuitable inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
	<keyword>Epratuzumab</keyword>
</DOC>